A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet beta-cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet beta-cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Human proislet peptide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors CureDM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Sep 2016 Status changed from recruiting to completed.
    • 05 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top